|
Market Research Report
Neurodegenerative Market Forecast to 2013
|
Neurodegenerative Market Forecast to 2013 published by Cutting Edge Information in February, 2009. This report consists of 201 Pages and the price starts from US $ 6995.
Abstract
Comprehensive Forecasts for Neurodegenerative Conditions
The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:
- Sales among all drugs profiled in this report total $18.5 billion and are
expected to increase 62% to $29.7 billion by 2012.
- The majority of this growth is projected to be in multiple sclerosis,
which will increase from a $12.6 billion market to upwards of $20 billion in
2012.
Neurodegenerative disease patients have few treatment options, which often
provide only limited effectiveness. Companies that can invest in and develop
new, tolerable therapies which improve patients' quality of life could see
hundreds of millions - or even billions - of dollars in sales.
In one convenient, easy-to-access format, Neurodegenerative Market Forecast to
2013 provides a compelling, full picture of the Alzheimer' s, Multiple
Sclerosis and Parkinson' s markets.
Detailed Product Profiles
CEI' s veteran analysts examine 40 brands representing different classes and
stages of development. The profiled products represent over 90% of sales in
the neurodegenerative market. Each drug profile has the following components:
- Drug history
- Competitive and strategic positioning:
- Current status of drug
- Sales position within its class
- Presence or strength of competition
- Market growth opportunities:
- Analysis combines new/current sales or clinical trial info with
projections, predictions, insights
- Analysis supported by sales projection charts, covering up to the next 7
years
- Materiality charts, for 2007 and 2012
- Charts containing market exclusivity and patent information for approved
drugs
- Clinical trial data tables to quickly show clinical detail:
- Describes trial and why drug is in its current stage
- Progress of drug
Table of Contents
Executive Summary
- Key Trends in the Neurodegenerative Disease Market
- Methodology and Definitions
Alzheimer' s Disease
- Acetylcholinesterase Inhibitors
- Aricept (donepezil)
- Exelon (rivastigmine tartrate
- Razadyne (galantamine)
- NMDA Antagonists
- Namenda (memantine HCI)
- Ebixa (memantine HCI)
- Amyloid Beta Therapies
- Bapineuzumab (AAB-001)
- Ly450139
- LY2062430
- ACC-001
- Other Alzheimer' s Therapies
- Abilify (aripiprazole)
- Dimebon (dimebolin)
- AZD3480/TC-1734 (ispronicline)
- SB-742457
- Tanakan (EGb751, standardized ginkgo biloba)
- Avandia XR (extended-release rosiglitazone)
- MEM 1003
Multiple Sclerosis
- Interferon Betas
- Avonex (interferon beta-1a)
- Rebif (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Immunomodulators
- Copaxone (glatiramer acetate)
- Fingolimod/FTY720
- BG-12/Oral Fumarate
- Laquinimod
- Oral Leustatin (cladribine)
- Teriflunomide/HMR 176
- Monoclonal Antibodies
- HuMax-CD20 (ofatumumab)
- Campath (alemtuzumab)
- Rituxan/Mabthera (rituximab)
- Tysabri/Antegren (natalizumab)
- Firategrast/SB683699
- Other Therapies
- Fampridine-SR (4-aminopyridine)
- Dirucotide/MBP 8298
Parkinson' s Disease
- Dopaminergic Drugs
- Comtan (entacapone)/Stalevo (combination)
- Mirapex (pramipexole)
- Sinemet (carbidopa + levodopa)
- Apokyn (apomorphine)
- Requip XL (ropinirole)
- Other Therapies
- Azilect/Agilect (rasagiline)
- ACP-103 (pimavanserin tartrate)
- Droxidopa
CHARTS AND GRAPHICS
Executive Summary
- Figure E.1: Total Sales for Neurodegenerative Indications, 2004-2012 (in
billions)
- Figure E.2: Total sales for Alzheimer' s Disease by Drug Class, 2006-2012
(in millions)
- Figure E.3: Top-Selling Alzheimer' s Drugs
- Figure E.4: Total Sales for Multiple Sclerosis by Drug Class, 2004-2012
(in millions)
- Figure E.5: Top-Selling Multiple Sclerosis Drugs
- Figure E.6: Total Sales for Parkinson' s by drug class, 2005-2012 (in
millions)
- Figure E.7: Top-Selling Parkinson' s Drugs
Alzheimer' s Disease
- Profiled Alzheimer' s Drugs
- Profiled Alzheimer' s Drugs, Continued
- Alzheimer' s Drug Sales: 2004-2012, In Billions
Acetylcholinesterase Inhibitors
- Profiled AChEl Inhibitors
- AChEl Sales: 2004-2012, in Millions
- Aricept (donepezil)
- Aricept Materiality to Eisai: 2007
- Aricept Materiality to Pfizer: 2007
- Aricept Sales: 2004-2012
- Exelon (rivastigmine tartrate)
- Exelon Materiality: 2007
- Exelon Materiality: 2012
- Exelon Sales: 2004-2015
- Razadyne (galantamine)
- Razadyne Materiality: 2007
- Razadyne Materiality: 2012
- Razadyne Sales: 2004-2012
NWDA Antagonists
- Profiled NMDA Antagonists
- NMDA Antagonist Sales: 2004-2012, in Millions
- Namenda (memantine HCI)
- Namenda Materiality: 2007
- Namenda Materiality: 2012
- Namenda Sales: 2004-2013
- Ebixa (memantine HCI)
- Ebixa Materiality: 2007
- Ebixa Materiality: 2012
- Ebixa Sales: 2004-2012
Amyloid Beta Therapies
- Profiled Drugs Targeting Amyloid Beta
- Amyloid Beta Drug Sales: 2004-2012, in Millions
- Bapineuzumab (AAB-001)
- Bapineuzumab Materiality: 2011
- Bapineuzumab Materiality: 2012
- Bapineuzumab Sales: 2011-2015
- LY450139
- LY450139 Materiality: 2012
- LY450139 Sales: 2012-2015
- LY2062430
- LY2062430 Materiality: 2012
- LY2062430 Sales: 2012-2015
- ACC-001
- ACC-001 Materiality: 2012
- ACC-001 Sales: 2012-2015
Other Therapies
- Profiled Alzheimer' s Drugs Targeting Other Neurotransmitters
- Other Profiled Alzheimer' s Drugs
- Alzheimer' s Neurotransmitter Sales, Excluding Ability: 2011-2015, in
Millions
- Other Alzheimer' s Drug Sales: 2005-2015, in Millions
- Abilify (aripiprazole)
- Abilify Materiality: 2007
- Abilify Materiality: 2012
- Abilify Sales: 2004-2014
- Dimebon (dimebolin)
- Dimebon Materiality to Pfizer: 2010
- Dimebon Materiality to Medivation: 2010
- Dimebon Materiality to Pfizer: 2012
- Dimebon Materiality to Medivation: 2012
- Dimebon Sales: 2011-2015
- AZD3480/TC-1734 (ispronicline)
- AZD3480 Materiality: 2011
- AZD3480 Materiality: 2012
- AZDE3480 Sales: 2012-2014
- SB-742457
- SB-742457 Materiality: 2012
- SB-742457 Sales: 2012-2015
- Tanakan (EGb751, standardized ginkgo biloba)
- Tanakan Materiality: 2007
- Tanakan materiality: 2012
- Tanakan Sales: 2012-2015
- Avandia XR (extended-release rosiglitazone)
- Avandia XR Materiality: 2012
- Avandia XR Sales: 2012-2015
- MEM 1003
Multiple Sclerosis
- Profiled Multiple Sclerosis Drugs
- Profiled Monoclonal Antibodies for Multiple Sclerosis
- Profiled Multiple Sclerosis Drugs, Continued
- Multiple Sclerosis Drug Sales: 2006-2012, in Billions
Interferon Betas
- Profiled Interferons
- Interferon Sales: 2006-2013, in Millions
- Avonex (interferon beta-1a)
- Avonex Materiality: 2007
- Avonex Materiality: 2012
- Avonex Sales: 2004-2013
- Rebif (interferon beta-1a)
- Rebif Materiality: 2007
- Rebif Materiality: 2012
- Rebif Sales: 2000-2013
- Betaseron (interferon beta-1b)
- Betaseron Materiality: 2007
- Betaseron Materiality: 2012
- Betaseron Sales: 2005-2014
- Immunomodulators
- Profiled Immunomodulators
- Immunomodulator Sales: 2006-2012, in Millions
- Copaxone (glatiramer acetate)
- Copaxone Materiality: 2007
- Copaxone Materiality: 2012
- Copaxone Sales: 2006-2012
- Fingolimod/FTY720
- Fingolimod Materiality: 2010
- Fingolimod Materiality: 2012
- Fingolimod Sales: 2010-2015
- BG-12/Oral Fumarate
- BG-12 Materiality: 2011
- BG-12 Materialtiy: 2012
- BG-12 Sales: 2011-2012
- Laquinimod
- Laquinimod Materiality: 2011
- Laquinimod Materiality: 2012
- Laquinimod Sales: 2011-2012
- Oral Leustatin (cladribine)
- Oral Leustatin Materiality: 2010
- Oral Leustatin Materiality: 2012
- Oral Leustatin Sales: 2010-2012
- Teriflunomide/HMR 1726
- Teriflunomide Materiality: 2013
- Teriflunomide Sales: 2013-2015
Monoclonal Antibodies
- Profiled Anti-CD20 & Anti-CD52Drugs
- Profiled VLA-4 Antibodies
- VLA-4 Antibody Sales: 2008-2012, in Millions
- HuMax-CD20 (ofatumumab)
- HuMax-CD20 Materiality: 2009
- HuMax-CD20 Materiality: 2012
- HuMax-CD20 Sales: 2009-2012
- Campath (alemtuzumab)
- Campath Materiality: 2007
- Campath Materiality: 2012
- Campath Sales: 2005-2012
- Rituxan/MabThera (rituximab)
- Materiality to Bl: 2007
- Materiality to Roche: 2007
- Materiality to Genentech: 2007
- Rituxan Sales: 2005-2015
- Tysabri/Antegren (natalizumab)
- Tysabri Materiality to Elan: 2007
- Tysabri Materiality to Biogen Idec: 2007
- Tysabri Materiality to Elan: 2012
- Tysabri Materiality to Biogen Idec: 2012
- Tysabri Sales: 2005-2012
- Firategrast/SB683699
- Firategrast Materiality: 2012
- Firategrast Sales: 2012-2015
Other Therapies
- Other Profiled MS Drugs
- Other MS Sales: 2009-2013, in Millions
- Fampridine-SR (4-aminopyridine)
- Materiality to Acorda: 2009
- Materiality to Elan: 2009
- Materiality to Acorda: 2012
- Materiality to Elan: 2012
- Fampridine-SR Sales: 2009-2013
- Dirucotide/MBP 8298
- Dirucotide Materiality: 2011
- Dirucotide Materiality: 2012
- Dirucotide Sales: 2011-2015
Parkinson' s Disease
- Profiled Parkinson' s Drugs
- Parkinson' s Drug Sales: 2005-2012, in Billions
Dopaminergic Drugs
- Profiled Dopaminergic Parkinson' s Drugs
- Dopaminergic Drug Sales: 2004-2012, in Millions
- Comtan (entacapone)/ Stalevo (combination)
- Comtan+Stalevo Materiality: 2007
- Comtan+Stalevo Materiality: 2012
- Somtan+Stalevo Sales: 2005-2015
- Mirapex (pramipexole)
- Mirapex Materiality: 2007
- Mirapex Materiality: 2011
- Mirapex Sales: 2005-2011
- Sinemet (caribidopa + levodopa)
- Sinemet Materiality: 2007
- Sinemet Materialtiy: 2012
- Sinemet Sales: 2007-2015
- Apokyn (apomorphine)
- Apokyn Materiality: 2007
- Apokyn Materiality: 2012
- Apokyn Sales: 2005-2012
- Requip XL (ropinirole)
- Requip XL Materiality: 2009
- Requip XL Materiality: 2009
- Requip XL Sales: 2009-2012
Other Therapies
- Other Profied Parkinson' s Drugs
- Other Parkinson' s Drug Sales: 2006-2012, in Millions
- Azilect/Agilect (rasagiline)
- Azilect Materiality: 2007
- Azilect Materiality: 2012
- Azilect Sales: 2006-2012
- ACP-103 (pimavanserin tartrate)
- ACP-103 Materiality: 2009
- ACP-103 Materiality: 2012
- ACP-103 Sales: 2009-2015
- Droxidopa
- Droxidopa Materiality: 2010
- Droxidopa Materiality: 2012
- Droxidopa Sales: 2010-2013
|
